Results 31 to 40 of about 112,374 (313)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction

Journal of Cardiovascular Development and Disease, 2023
Heart failure with reduced ejection fraction is a chronic and progressive syndrome that continues to be a substantial financial burden for health systems in Western countries. Despite remarkable advances in pharmacologic and device-based therapy over the
Luigi Falco, Benedetta Brescia, Dario Catapano, Maria Luigia Martucci, Fabio Valente, Rita Gravino, Carla Contaldi, Giuseppe Pacileo, Daniele Masarone   +8 more
doaj   +1 more source

Axial Muscle Size as a Strong Predictor of Death in Subjects With and Without Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background The impact of skeletal muscle size, quantified using simple noninvasive images routinely obtained during cardiac magnetic resonance imaging studies on mortality in the heart failure (HF) population is currently unknown.
Anupam Kumar, Bilal A. Ansari, Jessica Kim, Arpita Suri, Sowmya Gaddam, Sowjanya Yenigalla, Jagan M. Vanjarapu, Senthil Selvaraj, Dheera Tamvada, Jonathan Lee, Scott R. Akers, Julio A. Chirinos   +11 more
doaj   +1 more source

ST2 in heart failure with preserved and reduced ejection fraction [PDF]

Scandinavian Cardiovascular Journal, 2019
Soluble suppression of tumorigenecity 2 (sST2) is prognostic in acute and chronic heart failure with reduced ejection fraction (HFrEF) but less studied in HF with preserved EF (HFpEF). We evaluated sST2 concentrations, correlations with biomarkers and echocardiographic measures of diastolic and systolic function, and associations with outcomes in HFpEF
Jean-Claude Daubert, Ulrika Ljung Faxén, Ulrika Ljung Faxén, Camilla Hage, Camilla Hage, Cecilia Linde, Cecilia Linde, Erwan Donal, Lars H. Lund, Lars H. Lund, Emil Najjar, Emil Najjar   +11 more
openaire   +4 more sources

Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study

ESC Heart Failure, 2020
Aims Changes in echocardiographic parameters and biomarkers of cardiac and venous pressures or estimated plasma volume during hospitalization associated with decongestive treatments in acute heart failure (AHF) patients with either preserved left ...
Eiichi Akiyama, Raphaël Cinotti, Kamilė Čerlinskaitė, Lucas N.L. Van Aelst, Mattia Arrigo, Rui Placido, Tahar Chouihed, Nicolas Girerd, Faiez Zannad, Patrick Rossignol, Marc Badoz, Jean‐Marie Launay, Etienne Gayat, Alain Cohen‐Solal, Carolyn S.P. Lam, Jeffrey Testani, Wilfried Mullens, Gad Cotter, Marie‐France Seronde, Alexandre Mebazaa   +19 more
doaj   +1 more source

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction

Frontiers in Cardiovascular Medicine, 2019
Background: Although central apneas (CA) and obstructive apneas (OA) are highly prevalent in heart failure (HF), a comparison of apnea prevalence, predictors and clinical correlates in the whole HF spectrum, including HF with reduced ejection fraction ...
Chiara Borrelli, Chiara Borrelli, Chiara Borrelli, Francesco Gentile, Paolo Sciarrone, Gianluca Mirizzi, Gianluca Mirizzi, Giuseppe Vergaro, Giuseppe Vergaro, Nicolò Ghionzoli, Francesca Bramanti, Giovanni Iudice, Claudio Passino, Claudio Passino, Michele Emdin, Michele Emdin, Alberto Giannoni, Alberto Giannoni   +17 more
doaj   +1 more source

Clinical characteristics and outcomes of heart failure with preserved, mildly reduced, and reduced ejection fraction: A 6-month follow-up study

Medical Journal of Babylon, 2022
Background and Objective: Heart failure is a major public health problem with 64.3 million people affected all over the world, and it is an important cause for hospital admission and mortality.
Goran Adnan Rahman, Abdulkareem Abdulwahab Al-Othman   +1 more
doaj   +1 more source

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

ESC Heart Failure, 2022
Aims Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower ...
Michele Senni, Jose Lopez‐Sendon, Alain Cohen‐Solal, Piotr Ponikowski, Richard Nkulikiyinka, Cecilia Freitas, Vanja Miodrag Vlajnic, Lothar Roessig, Burkert Pieske   +8 more
doaj   +1 more source

Relationship Between Dietary Magnesium Intake and Incident Heart Failure Among Older Women: The WHI

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Women represent a large proportion of the growing heart failure (HF) epidemic, yet data are lacking regarding optimal dietary and lifestyle prevention strategies for them.
Wen‐Chih Wu, Mengna Huang, Tracey H. Taveira, Mary B. Roberts, Lisa W. Martin, Gregory A. Wellenius, Karen C. Johnson, JoAnn E. Manson, Simin Liu, Charles B. Eaton   +9 more
doaj   +1 more source

Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction [PDF]

Journal of the American College of Cardiology, 2020
Microvascular dysfunction plays an important role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). However, no mechanistic link between systemic microvasculature and congestion, a central feature of the syndrome, has yet been investigated.This study aimed to investigate capillary-interstitium fluid exchange in HFpEF ...
Giacomo Rossitto, Giacomo Rossitto, Christian Delles, Christine McAllister, Sheon Mary, John Paul Rocchiccioli, Mark C. Petrie, Ninian Nicholas Lang, Rhian M. Touyz, Clare Murphy, Karla B Neves, Laura Haddow   +11 more
openaire   +4 more sources

Soft Beats: A Dielectric Elastomer‐Based Ventricular Assist Device for Next‐Gen Heart Failure Management

Advanced Engineering Materials, EarlyView.
The dielectric elastomer‐based electropneumatic device (DE‐EPD) is a vacuum‐assisted ventricular assist device (VAD) that delivers high performance (85 mmHg, 6.8 L min−1) with low power consumption. Unlike traditional motor‐driven VADs, it is lightweight, quiet, energy‐efficient, and provides pulsatile flow. Validated in a simulated circulation system,
Amine Benouhiba, Armando Walter, Silje Ekroll Jahren, Francesco Clavica, Dominik Obrist, Yoan Civet, Yves Perriard   +6 more
wiley   +1 more source